Heidelberg Pharma Reports on First Half-Year 2021
- HDP-101: Application to initiate clinical trial green-lighted by the FDA in February 2021; Clinical trial centers prepare to receive their first patient; Clinical Trial Application submitted to the Paul Ehrlich Institute in Germany
- New preclinical data on the immunomodulatory potential of Antibody Targeted Amanitin Conjugates presented at the AACR 2021 Annual Meeting
- Various financing measures secure liquidity and development program until mid-2022
- Operating result in line with planning; progress made in development program leads to increased research and development costs
- Public conference call to be held on 8 July 2021 at 3:00 pm CEST
Heidelberg Pharma AG today published its financial report on the first six months of 2021 (1 December 2020 – 31 May 2021).
Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “FDA approval of the Phase I trial with HDP-101 was an important milestone for us as we move our first Antibody Targeted Amanitin Conjugate into clinical development. We were also able to raise EUR 20 million in a private placement to further advance our three proprietary ATAC programs. These are the next important steps for HDP-101: Approval of the study protocol for Germany by the Paul Ehrlich Institute and start of the trial in the US.